CoChat
Sign Up
Cited by 125

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Pleyer, Lisa, Egle, Alexander, Hartmann, Tanja Nicole, Greil, Richard·2009·Nature Reviews Clinical Oncology
DOI 10.1038/nrclinonc.2009.72
Open this paper in CoChat — free account

Abstract

The mainstay of therapy of chronic lymphocytic leukemia (CLL) is cytotoxic chemotherapy; however, CLL is still an incurable disease with resistance to therapy developing in the majority of patients. In recent years, our understanding of the biological basis of CLL pathogenesis has substantially improved and novel treatment strategies are emerging. Tailoring and individualizing therapy according to the molecular and cellular biology of the disease is on the horizon, and advances with targeted agents such as monoclonal antibodies combined with traditional chemotherapy have lead to improved remission rates. The proposed key role of the B-cell receptor (BCR) in CLL pathogenesis has led to a number of possible opportunities for therapeutic exploitation. We are beginning to understand that the microenvironment is of utmost importance in CLL because certain T-cell subsets and stromal cells support the outgrowth and development of the malignant clone. Furthermore, an increase in our understanding of the deregulated cell-death machinery in CLL is a prerequisite to developing new targeted strategies that might be more effective in engaging with the cell-death machinery. This Review summarizes the progress made in understanding these features of CLL biology and describes novel treatment strategies that have also been exploited in current clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2009.72

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 140

  1. Moreton, P. et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol. 23, 2971–2979 (2005). · DOI
  2. Bosch, F. et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin. Cancer Res. 14, 155–161 (2008). · DOI
  3. Lamanna, N. et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J. Clin. Oncol. 27, 491–497 (2009). · DOI
  4. Boettcher, S. et al. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab—a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial [abstract]. Blood 112, a326 (2008). · DOI
  5. Keating, M. J. et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4079–4088 (2005). · DOI
  6. Dohner, H. et al. P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85, 1580–1589 (1995). · DOI
  7. Byrd, J. C. et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J. Clin. Oncol. 24, 437–443 (2006). · DOI
  8. Xu, J. L. & Davis, M. M. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13, 37–45 (2000). · DOI · Paper page
  9. Maizels, N. Immunoglobulin gene diversification. Annu. Rev. Genet. 39, 23–46 (2005). · DOI
  10. William, J. et al. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 297, 2066–2070 (2002). · DOI
  11. Chiorazzi, N. & Ferrarini, M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu. Rev. Immunol. 21, 841–894 (2003). · DOI
  12. Messmer, B. T. et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J. Exp. Med. 200, 519–525 (2004). · DOI
  13. Murray, F. et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 111, 1524–1533 (2008). · DOI
  14. Damle, R. N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840–1847 (1999). · DOI
  15. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. & Stevenson, F. K. Unmutated Ig V-H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848–1854 (1999). · DOI
  16. Rosenwald, A. et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 194, 1639–1647 (2001). · DOI
  17. Klein, U. et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 194, 1625–1638 (2001). · DOI
  18. Damle, R. N. et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 99, 4087–4093 (2002). · DOI
  19. Stamatopoulos, K. et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 109, 259–270 (2007). · DOI
  20. Athanasiadou, A. et al. Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins. Haematologica 93, 473–474 (2008). · DOI
  21. Mauerer, K. et al. Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. Br. J. Haematol. 129, 499–510 (2005). · DOI
  22. Hamblin, T. J. Prognostic markers in chronic lympocytic leukaemia. Best Pract. Res. Clin. Haematol. 20, 455–468 (2007). · DOI
  23. Contri, A. et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J. Clin. Invest. 115, 369–378 (2005). · DOI
  24. Longo, P. G. et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 111, 846–855 (2008). · DOI
  25. Fujimoto, M., Poe, J. C., Jansen, P. J., Sato, S. & Tedder, T. F. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J. Immunol. 162, 7088–7094 (1999). · DOI
  26. Alfarano, A. et al. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood 93, 2327–2335 (1999). · DOI
  27. Lankester, A. C. et al. Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. Blood 86, 1090–1097 (1995). · DOI
  28. Gobessi, S. et al. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 109, 2032–2039 (2007). · DOI
  29. Wiestner, A. et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101, 4944–4951 (2003). · DOI
  30. Durig, J. et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 17, 2426–2434 (2003). · DOI
  31. Mockridge, C. I. et al. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 109, 4424–4431 (2007). · DOI
  32. Efremov, D. G., Gobessi, S. & Longo, P. G. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun. Rev. 7, 102–108 (2007). · DOI
  33. Allsup, D. J. et al. B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. Cancer Res. 65, 7328–7337 (2005). · DOI
  34. Deaglio, S., Vaisitti, T., Aydin, S., Ferrero, E. & Malavasi, F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 108, 1135–1144 (2006). · DOI
  35. Cockayne, D. A. et al. Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses. Blood 92, 1324–1333 (1998). · DOI
  36. Deaglio, S. et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood 109, 5390–5398 (2007). · DOI
  37. Deaglio, S. et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 110, 4012–4021 (2007). · DOI
  38. Muzio, M. et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 112, 188–195 (2008). · DOI
  39. Veldurthy, A. et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 112, 1443–1452 (2008). · DOI
  40. Garg, R. J. et al. Phase II study of dasatinib in patients with relapsed CLL [abstract]. Blood 112, a4197 (2008). · DOI
  41. Castro, J. E. et al. A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Evaluation of two dose regimens [abstract 3119]. Blood 110, 917A–918A (2007). · DOI
  42. Hallaert, D. Y. et al. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL [abstract 3078]. Blood 110, 905A (2007). · DOI
  43. Amrein, P. C. et al. A phase II study of dasatinib in relapsed and refractory chronic lymphocytic leukemia (CLL/SLL) [abstract 3126]. Blood 110, 920A (2007). · DOI
  44. Hirsch, C. L., Smith-Windsor, E. L. & Bonham, K. Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells. Int. J. Cancer 118, 547–554 (2006). · DOI
  45. Michie, A. M. & Nakagawa, R. Elucidating the role of protein kinase C in chronic lymphocytic leukaemia. Hematol. Oncol. 24, 134–138 (2006). · DOI
  46. Alkan, S. et al. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am. J. Hematol. 79, 97–106 (2005). · DOI
  47. Abrams, S. T. et al. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood 109, 1193–1201 (2007). · DOI
  48. Barragan, M. et al. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase Cβ. J. Leukoc. Biol. 80, 1473–1479 (2006). · DOI
  49. Ringshausen, I. et al. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia 20, 514–520 (2006). · DOI
  50. Nakagawa, R., Soh, J. W. & Michie, A. M. Subversion of protein kinase C alpha signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo. Cancer Res. 66, 527–534 (2006). · DOI
  51. Wojciechowski, W., Li, H., Marshall, S., Dell'Agnola, C. & Espinoza-Delgado, I. Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms. J. Immunol. 174, 7859–7868 (2005). · DOI
  52. Jazirehi, A. R., Vega, M. I., Chatterjee, D., Goodglick, L. & Bonavida, B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab. Cancer Res. 64, 7117–7126 (2004). · DOI
  53. Marzo, I. et al. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18, 1599–1604 (2004). · DOI
  54. Smal, C. et al. Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2'-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB. Biochem. Pharmacol. 73, 351–358 (2007). · DOI
  55. Caligaris-Cappio, F. & Ghia, P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J. Clin. Oncol. 26, 4497–4503 (2008). · DOI
  56. Ghia, P., Granziero, L., Chilosi, M. & Caligaris-Cappio, F. Chronic B cell malignancies and bone marrow microenvironment. Semin. Cancer Biol. 12, 149–155 (2002). · DOI
  57. Mackus, W. J. M. et al. Expansion of CMV-specific CD8+CD45RA+CD27− T cells in B-cell chronic lymphocytic leukemia. Blood 102, 1057–1063 (2003). · DOI
  58. Pedersen, I. M. & Reed, J. C. Microenvironmental interactions and survival of CLL B-cells. Leuk. Lymphoma 45, 2365–2372 (2004). · DOI
  59. Burger, J. A., Burger, M. & Kipps, T. J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94, 3658–3667 (1999). · DOI
  60. Mainou-Fowler, T., Miller, S., Proctor, S. J. & Dickinson, A. M. The levels of TNF alpha, IL4 and IL10 production by T-cells in B-cell chronic lymphocytic leukaemia (B-CLL). Leuk. Res. 25, 157–163 (2001). · DOI
  61. Hamblin, A. D. & Hamblin, T. J. The immunodeficiency of chronic lymphocytic leukaemia. Br. Med. Bull. 87, 49–62 (2008). · DOI
  62. Sinisalo, M. et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br. J. Haematol. 114, 107–110 (2001). · DOI
  63. Serrano, D. et al. Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J. Immunol. 158, 1482–1489 (1997). · DOI
  64. Kay, N. E., Johnson, J. D., Stanek, R. & Douglas, S. D. T-cell subpopulations in chronic lymphocytic leukemia: abnormalities in distribtuion and in in vitro receptor maturation. Blood 54, 540–544 (1979). · DOI
  65. Totterman, T. H., Carlsson, M., Simonsson, B., Bengtsson, M. & Nilsson, K. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 74, 786–792 (1989). · DOI
  66. Trojan, A. et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat. Med. 6, 667–672 (2000). · DOI
  67. Ranheim, E. A. & Kipps, T. J. Activated T-cells induce expression of B7/Bb1 on normal or leukemic B-cells through a Cd40-dependent signal. J. Exp. Med. 177, 925–935 (1993). · DOI
  68. Ramsay, A. G. et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 118, 2427–2437 (2008).
  69. Frolova, E. A., Scott, S. C. & Jones, R. A. Cd45Ro+ T-cells immunoregulate spontaneous in vitro immunoglobulin production by normal and chronic lymphocytic-leukemia B-cells. Leuk. Lymphoma 18, 103–111 (1995). · DOI
  70. Scrivener, S., Kaminski, E. R., Demaine, A. & Prentice, A. G. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br. J. Haematol. 112, 959–964 (2001). · DOI
  71. Tivol, E. A. et al. Loss of Ctla-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of Ctla-4. Immunity 3, 541–547 (1995). · DOI · Paper page
  72. Luqman, M. et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 112, 711–720 (2008). · DOI
  73. Messmer, D. & Kipps, T. J. CD154 gene therapy for human B-cell malignancies. Ann. NY Acad. Sci. 1062, 51–60 (2005). · DOI
  74. Biagi, E. et al. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood 105, 2436–2442 (2005). · DOI
  75. Ghia, P. et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur. J. Immunol. 32, 1403–1413 (2002). · DOI
  76. Chilosi, M. et al. Immunohistochemical demonstration of follicular dendritic cells in bone-marrow involvement of B-cell chronic lymphocytic-leukemia. Cancer 56, 328–332 (1985). · DOI
  77. Ghia, P. et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101, 1262–1269 (2003). · DOI
  78. Patten, P. E. M. et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 111, 5173–5181 (2008). · DOI · Paper page
  79. Tinhofer, I. et al. Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 108, 2950–2956 (2006). · DOI
  80. Deaglio, S., Aydin, S., Vaisitti, T., Bergui, L. & Malavasi, F. CD38 at the junction between prognostic marker and therapeutic target. Trends Mol. Med. 14, 210–218 (2008). · DOI
  81. Kretz-Rommel, A. & Bowdish, K. S. Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression. Expert Opin. Biol. Ther. 8, 5–15 (2008). · DOI
  82. Lagneaux, L., Delforge, A., Bron, D., De Bruyn, C. & Stryckmans, P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91, 2387–2396 (1998). · DOI
  83. Ogata, T., Yamakawa, M., Imai, Y. & Takahashi, T. Follicular dendritic cells adhere to fibronectin and laminin fibers via their respective receptors. Blood 88, 2995–3003 (1996). · DOI
  84. Ansel, K. M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309–314 (2000). · DOI
  85. Trentin, L. et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 104, 502–508 (2004). · DOI
  86. Burger, M. et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106, 1824–1830 (2005). · DOI
  87. Till, K. J. et al. CLL, but not normal, B cells are dependent on autocrine VEGF and alpha(4) beta(1) integrin for chemokine-induced motility on and through endothelium. Blood 105, 4813–4819 (2005). · DOI
  88. Alfonso-Perez, M. et al. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J. Leukoc. Biol. 79, 1157–1165 (2006). · DOI
  89. List, A. F. Lenalidomide—the phoenix rises. N. Engl. J. Med. 357, 2183–2186 (2007). · DOI
  90. Richardson, P. Management of the relapsed/refractory myeloma patient: Strategies incorporating lenalidomide. Semin. Hematol. 42 (4 Suppl. 4), S9–S15 (2005). · DOI
  91. Mitsiades, C. S., Hayden, P. J., Anderson, K. C. & Richardson, P. G. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract. Res. Clin. Haematol. 20, 797–816 (2007). · DOI
  92. Chanan-Khan, A. et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J. Clin. Oncol. 24, 5343–5349 (2006). · DOI
  93. Ferrajoli, A. et al. Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) carrying unfavorable chromosomal abnormalities [abstract]. Blood 110, 754A (2007). · DOI
  94. Andritsos, L. A. et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J. Clin. Oncol. 26, 2519–2525 (2008). · DOI
  95. Carlo-Stella, C. et al. Targeting TRAIL agonistic receptors for cancer therapy. Clin. Cancer Res. 13, 2313–2317 (2007). · DOI
  96. Adams, J. M. & Cory, S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr. Opin. Immunol. 19, 488–496 (2007). · DOI
  97. Tinhofer, I. et al. Inversion of CD4+/CD8+ ratio in B chronic lymphocytic leukemia correlates with differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (APO-1/CD95) ligand(+) tumor cells. Blood 92, 271B (1998).
  98. Proto-Siqueira, R. et al. SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood 112, 394–397 (2008). · DOI
  99. Chu, P. et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 3854–3859 (2002). · DOI
  100. Anether, G., Tinhofer, I., Senfter, M. & Greil, R. Tetrocarcin-A-induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2-independent pathway. Blood 101, 4561–4568 (2003). · DOI
  101. Kater, A. P. et al. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 106, 1742–1748 (2005). · DOI
  102. Dicker, F., Kater, A. P., Fukuda, T. & Kipps, T. J. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood 105, 3193–3198 (2005). · DOI
  103. Inoue, S. et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11 (Suppl. 2), S193–S206 (2004). · DOI
  104. MacFarlane, M. et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ. 12, 773–782 (2005). · DOI
  105. Hallaert, D. Y. et al. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 112, 5141–5149 (2008). · DOI
  106. Smit, L. A. et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 109, 1660–1668 (2007). · DOI
  107. Willimott, S., Baou, M., Naresh, K. & Wagner, S. D. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br. J. Haematol. 138, 721–732 (2007). · DOI
  108. Mackus, W. J. M. et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 19, 427–434 (2005). · DOI
  109. Stankovic, T. et al. Microarray analysis reveals that TP53-and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 103, 291–300 (2004). · DOI
  110. Morales, A. A. et al. Expression and transcriptional regulation of functionally distinct Bmf isoforms in B-chronic lymphocytic leukemia cells. Leukemia 18, 41–47 (2004). · DOI
  111. Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231–241 (1997). · DOI · Paper page
  112. Qi, X. J., Wildey, G. M. & Howe, P. H. Evidence that Ser(87) of Bim(EL) is phosphorylated by Akt and regulates BimEL apoptotic function. J. Biol. Chem. 281, 813–823 (2006). · DOI
  113. Pekarsky, Y. et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 66, 11590–11593 (2006). · DOI
  114. Calin, G. A. et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc. Natl Acad. Sci. USA 105, 5166–5171 (2008). · DOI
  115. Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944–13949 (2005). · DOI
  116. Gowda, A. et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 111, 4723–4730 (2008). · DOI
  117. Zenz, T. et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112, 3322–3329 (2008). · DOI
  118. Austen, B. et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J. Clin. Oncol. 25, 5448–5457 (2007). · DOI
  119. Gryshchenko, I. et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J. Clin. Oncol. 26, 2252–2257 (2008). · DOI
  120. Yin, X. M. et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400, 886–891 (1999). · DOI · Paper page
  121. Dicker, F. et al. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 108, 3450–3457 (2006). · DOI
  122. O'Brien, S. et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 25, 1114–1120 (2007). · DOI
  123. O'Brien, S. M. et al. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J. Clin. Oncol. 23, 7697–7702 (2005). · DOI
  124. Labi, V., Grespi, F., Baumgartner, F. & Villunger, A. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ. 15, 977–987 (2008). · DOI
  125. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005). · DOI
  126. Trudel, S. et al. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015–070) in multiple myeloma. Blood 109, 5430–5438 (2007). · DOI
  127. Nguyen, M. et al. Small molecule obatoclax (GX15–070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl Acad. Sci. USA 104, 19512–19517 (2007). · DOI
  128. O'Brien, S. M. et al. Phase I study of obatoclax mesylate (GX15–070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113, 299–305 (2008). · DOI
  129. Wilson, W. H. et al. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies [abstract]. J. Clin. Oncol. 26, a8511 (2008). · DOI
  130. Balakrishnan, K., Burger, J. A., Wierda, W. G. & Gandhi, V. AT-101 induces apoptosis in CLL B-cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113, 149–153 (2008). · DOI
  131. Aloyz, R. et al. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 18, 409–414 (2004). · DOI
  132. Mansour, A., Chang, V. T., Srinivas, S., Harrison, J. & Raveche, E. Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein. Cancer Immunol. Immunother. 56, 501–514 (2007). · DOI
  133. Ganeshaguru, K. et al. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica 87, 167–176 (2002).
  134. Varterasian, M. L. et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin. Cancer Res. 6, 825–828 (2000).
  135. Roberts, J. D. et al. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin. Cancer Res. 12, 5809–5816 (2006). · DOI
  136. Galli, U. et al. Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. ChemMedChem. 3, 771–779 (2008). · DOI
  137. Rhodes, N. et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68, 2366–2374 (2008). · DOI
  138. Zeng, Z. et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol. Cancer Ther. 5, 3113–3121 (2006). · DOI
  139. Cornall, R. J. et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 8, 497–508 (1998). · DOI
  140. Xu, Y., Beavitt, S. J., Harder, K. W., Hibbs, M. L. & Tarlinton, D. M. The activation and subsequent regulatory roles of Lyn and CD19 after B cell receptor ligation are independent. J. Immunol. 169, 6910–6918 (2002). · DOI

Cited by

See all 125

Metadata

Authors
Pleyer, L., Egle, A., Hartmann, T. N., & Greil, R.
Venue
Nature Reviews Clinical Oncology
Publisher
Springer Science and Business Media LLC
Published
2009-06-02
Volume
6
Issue
7
Pages
405-418
ISSN
  • 1759-4774
  • 1759-4782
DOI
10.1038/nrclinonc.2009.72
Cited by
125
References
1
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular and cellular mechanisms of CLL: novel therapeutic approaches. https://app.cochat.ai/papers/10.1038/nrclinonc.2009.72
The paper
Pleyer, L., Egle, A., Hartmann, T. N., & Greil, R. (2009). Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nature Reviews Clinical Oncology. https://doi.org/10.1038/nrclinonc.2009.72